Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

20.05.2024

1 Ann Neurol
1 Eur Neurol
1 J Clin Invest
3 J Neurol
4 J Neurol Neurosurg Psychiatry
1 JAMA
6 Mult Scler
2 Neurology
1 Rev Neurol (Paris)



    Ann Neurol

  1. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    >> Share


    Eur Neurol

  2. KIZILAY T, Akbayir E, Erol R, Demir AS, et al
    Altered cerebrospinal fluid neurofilament light chain but not neurogranin levels are associated with response to ocrelizumab treatment in relapsing remitting multiple sclerosis: a preliminary study.
    Eur Neurol. 2024 May 16. doi: 10.1159/000539376.
    >> Share


    J Clin Invest

  3. GHORBANI S, Li C, Lozinski BM, Moezzi D, et al
    Fibulin-2 is an extracellular matrix inhibitor of oligodendrocytes relevant to multiple sclerosis.
    J Clin Invest. 2024 May 14:e176910. doi: 10.1172/JCI176910.
    >> Share


    J Neurol

  4. CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
    Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
    >> Share

  5. WOLF E, Wicklein R, Aly L, Schmaderer C, et al
    Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
    >> Share

  6. FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
    The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
    >> Share


    J Neurol Neurosurg Psychiatry

  7. ROCCA MA, Valsasina P, Romano F, Tedone N, et al
    Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol Neurosurg Psychiatry. 2024 May 16:jnnp-2024-333460.
    >> Share

  8. ENGLUND S, Frisell T, Qu Y, Gandhi K, et al
    Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2024-333595.
    >> Share

  9. VIRTANEN S, Piehl F, Frisell T
    Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2023-333206.
    >> Share

  10. THIEL S, Litvin N, Haben S, Gold R, et al
    Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy.
    J Neurol Neurosurg Psychiatry. 2024;95:561-570.
    >> Share


    JAMA

  11. HARRIS E
    Autoantibody Profile Emerged Years Before Multiple Sclerosis Diagnosis.
    JAMA. 2024 May 17. doi: 10.1001/jama.2024.8428.
    >> Share


    Mult Scler

  12. DAGNEW B, Laslett LL, Honan CA, Blizzard L, et al
    The association of comorbidities with sleep quality among Australians with multiple sclerosis: Insights from the Australian Multiple Sclerosis Longitudinal Study.
    Mult Scler. 2024 May 13:13524585241248278. doi: 10.1177/13524585241248278.
    >> Share

  13. COLLORONE S, Coll L, Lorenzi M, Llado X, et al
    Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis.
    Mult Scler. 2024 May 13:13524585241249422. doi: 10.1177/13524585241249422.
    >> Share

  14. HEWARD KD, Roy-Hewitson C, Solomon AJ
    Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria.
    Mult Scler. 2024 May 15:13524585241253513. doi: 10.1177/13524585241253513.
    >> Share

  15. NAIZER H, Wozny J, Krause TM, Huson E, et al
    Trends in central nervous system-active polypharmacy among people with multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241251986. doi: 10.1177/13524585241251986.
    >> Share

  16. WICKLEIN R, Kreitner L, Wild A, Aly L, et al
    Retinal small vessel pathology is associated with disease burden in multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241247775. doi: 10.1177/13524585241247775.
    >> Share

  17. LEBRUN-FRENAY C, Okuda DT
    Time to move past typical syndromes in the diagnosis of multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241253519. doi: 10.1177/13524585241253519.
    >> Share


    Neurology

  18. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    >> Share

  19. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    >> Share


    Rev Neurol (Paris)

  20. GAUTHIER H, Zedet M, Wahab A, Balde S, et al
    Metabolic syndrome and the phenotype of multiple sclerosis.
    Rev Neurol (Paris). 2024 May 9:S0035-3787(24)00502.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016